Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Unresectable Recurrent or Metastatic Head and Neck Cancer
NCT02762513Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Aug 2016
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by University of Michigan Rogel Cancer Center. Started Aug 2016; status: completed.
02
Drugs
axitinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02762513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762513.